Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 874

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Identification of Genes Upregulated in ALK -Positive and EGFR/KRAS/ALK -Negative Lung Adenocarcinomas

Open access
Okayama, Hirokazu, Kohno, Takashi, Ishii, Yuko, Shimada, Yoko, Shiraishi, Kouya, Iwakawa, Reika, Furuta, Koh, Tsuta, Koji, Shibata, Tatsuhiro, Yamamoto, Seiichiro, Watanabe, Shun-ichi, Sakamoto, Hiromi, Kumamoto, Kensuke, Takenoshita, Seiichi, Gotoh, Noriko, Mizuno, Hideaki, Sarai, Akinori, Kawano, Shuichi, Yamaguchi, Rui, Miyano, Satoru, Yokota, Jun·2012·Cancer Research

Abstract

Activation of the EGFR, KRAS, and ALK oncogenes defines 3 different pathways of molecular pathogenesis in lung adenocarcinoma. However, many tumors lack activation of any pathway (triple-negative lung adenocarcinomas) posing a challenge for prognosis and treatment. Here, we report an extensive genome-wide expression profiling of 226 primary human stage I–II lung adenocarcinomas that elucidates molecular characteristics of tumors that harbor ALK mutations or that lack EGFR, KRAS, and ALK mutations, that is, triple-negative adenocarcinomas. One hundred and seventy-four genes were selected as being upregulated specifically in 79 lung adenocarcinomas without EGFR and KRAS mutations. Unsupervised clustering using a 174-gene signature, including ALK itself, classified these 2 groups of tumors into ALK-positive cases and 2 distinct groups of triple-negative cases (groups A and B). Notably, group A triple-negative cases had a worse prognosis for relapse and death, compared with cases with EGFR, KRAS, or ALK mutations or group B triple-negative cases. In ALK-positive tumors, 30 genes, including ALK and GRIN2A, were commonly overexpressed, whereas in group A triple-negative cases, 9 genes were commonly overexpressed, including a candidate diagnostic/therapeutic target DEPDC1, that were determined to be critical for predicting a worse prognosis. Our findings are important because they provide a molecular basis of ALK-positive lung adenocarcinomas and triple-negative lung adenocarcinomas and further stratify more or less aggressive subgroups of triple-negative lung ADC, possibly helping identify patients who may gain the most benefit from adjuvant chemotherapy after surgical resection. Cancer Res; 72(1); 100–11. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-1403

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 874

Metadata

Authors
Okayama, H., Kohno, T., Ishii, Y., Shimada, Y., Shiraishi, K., Iwakawa, R., Furuta, K., Tsuta, K., Shibata, T., Yamamoto, S., Watanabe, S.-I., Sakamoto, H., Kumamoto, K., Takenoshita, S., Gotoh, N., Mizuno, H., Sarai, A., Kawano, S., Yamaguchi, R., Miyano, S., & Yokota, J.
Venue
Cancer Research
Published
2012-01-01
Volume
72
Issue
1
Pages
100-111
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2155354546
Cited by
874
References
37
FWCI
18.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Genes Upregulated in ALK -Positive and EGFR/KRAS/ALK -Negative Lung Adenocarcinomas. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-1403
The paper
Okayama, H., Kohno, T., Ishii, Y., Shimada, Y., Shiraishi, K., Iwakawa, R., Furuta, K., Tsuta, K., Shibata, T., Yamamoto, S., Watanabe, S.-I., Sakamoto, H., Kumamoto, K., Takenoshita, S., Gotoh, N., Mizuno, H., Sarai, A., Kawano, S., Yamaguchi, R., . . . Yokota, J. (2012). Identification of Genes Upregulated in ALK -Positive and EGFR/KRAS/ALK -Negative Lung Adenocarcinomas. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-1403

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.